CSM Announces Pilot Results of Subject Retention and Compliance Services for Clinical Trials
Following the completion of extensive pilot studies involving over 3,000 subjects in several clinical trials, CSM announces results demonstrating the effectiveness of its pioneering services in improving subject retention and compliance.
FARGO, ND -- May 11, 2005 -- Following the completion of extensive pilot studies involving over 3,000 subjects in several clinical trials, CSM announces results demonstrating the effectiveness of its pioneering services in improving subject retention and compliance.
These services employ a team of Clinical Trial Research Pharmacists (CTRP) who serve as a critical communication link between all clinical trial stakeholders (sponsors, CROs, investigators, subjects) throughout the trial, 24 hours a day, 7 days a week. CTRP are licensed pharmacists with expertise in clinical trials, drug issues, and subject counseling. Analysis of data collected during the pilot phase indicates that CTRP counseling helped studies meet or exceed expected subject retention rates in every case. In addition, over half of enrolled subjects per trial had a critical intervention, defined as a CTRP intervention that if left undetected or uncorrected would have compromised the quality of the data point.
The pilot studies showed that CTRP services benefited not only the sponsors, but other key study team members as well. Site monitors noted that the frequent CTRP reports helped escalate and resolve critical subject issues in a timely manner, while clinical research coordinators reported that the personalized service of the CTRP team and their 24/7 availability greatly improved communication and subject satisfaction in the studies.
"We are excited about the data from our pilot studies--it confirms the value of the service. In light of the FDA's recent critical path initiative to speed up the drug development process, we feel that CTRP services are needed now more than ever to facilitate the process, support good subject care, and ensure the best clinical data possible," said Tina Schlecht, Pharm.D., Vice President, Retention and Compliance Services.
CTRP services are currently available domestically and will benefit any clinical trial, especially those that involve a complicated drug regimen, dose titration, or use of a medical device to administer drug, or in trials where subject retention or compliance with protocol directions is critical.
About CSM
CSM is a clinical trial support services company committed to advancing clinical trials for pharmaceutical and biotechnology companies by providing innovative and customized services in the areas of clinical supplies and subject retention and compliance.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
